Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10689377 | MIRATI THERAPS | KRas G12C inhibitors |
May, 2037
(13 years from now) |
Krazati is owned by Mirati Theraps.
Krazati contains Adagrasib.
Krazati has a total of 1 drug patent out of which 0 drug patents have expired.
Krazati was authorised for market use on 12 December, 2022.
Krazati is available in tablet;oral dosage forms.
Krazati can be used as treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda approved test, who have received at least one prior systemic therapy.
Drug patent challenges can be filed against Krazati from 12 December, 2026.
The generics of Krazati are possible to be released after 17 May, 2037.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 12, 2027 |
Orphan Drug Exclusivity(ODE-352) | Dec 12, 2029 |
Drugs and Companies using ADAGRASIB ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 12 December, 2022
Treatment: Treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda approved test, who have received at least one prior system...
Dosage: TABLET;ORAL